Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-operative radiotherapy plus nivolumab + ipilimumab versus radiotherapy plus capecitabine in triple-negative breast cancer with residual disease
2017-003151-34Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Radiotherapy + nivolumab + ipilimumab with Radiotherapy + capecitabine (2 arms). Primary endpoint: Disease-free survival. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2017-003151-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003151-34.